Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BID | P55957 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.41 |
| ▸ | IAPP | P10997 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453232 | 0.95 | LIPG (0.51) | TSHRLIPGCYP3A4TP53MAPK1 | |
| SCHEMBL18519295 | 0.93 | LIPG (0.54) | TSHRLIPGALDH1A1LMNABID | |
| SCHEMBL28468212 | 0.93 | LIPG (0.54) | TSHRLIPGALDH1A1LMNABID | |
| SCHEMBL9456049 | 0.93 | LIPG (0.54) | TSHRLIPGALDH1A1LMNABID | |
| SCHEMBL11569404 | 0.93 | LIPG (0.54) | TSHRLIPGALDH1A1LMNABID | |
| SCHEMBL9456266 | 0.93 | LIPG (0.54) | TSHRLIPGALDH1A1LMNABID | |
| SCHEMBL11570752 | 0.93 | LIPG (0.54) | TSHRLIPGALDH1A1LMNABID | |
| SCHEMBL1900362 | 0.89 | FOLH1 (0.48) | FOLH1TSHRHTTTDP1L3MBTL1 | |
| SCHEMBL1404026 | 0.85 | TSHR (0.47) | FOLH1TSHRLIPGHTTTDP1 | |
| SCHEMBL2567958 | 0.85 | TSHR (0.47) | FOLH1TSHRLIPGHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630518-B2 | Process for preparing 1,2-benzisothiazoline-3-one | THOR GMBH (DE) | 2026-05-19 | — | — | US | disclosed |
| US-20240076276-A1 | Process for Preparing 1,2-Benzisothiazoline-3-One | THOR GMBH (DE) | 2024-03-07 | — | — | US | disclosed |
| EP-4237407-A1 | PROCESS FOR PREPARING 1,2-BENZISOTHIAZOLINE-3-ONE | THOR GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| CN-116457337-A | Method for preparing 1, 2-benzisothiazolin-3-one | 托尔有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022089774-A1 | PROCESS FOR PREPARING 1,2-BENZISOTHIAZOLINE-3-ONE | THOR GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| EP-2496549-B1 | NEW, NON-CRYSTALLISING METHACRYLATE, ITS MANUFACTURE AND APPLICATION | BAYER IP GMBH (DE) | 2014-10-08 | — | — | EP | disclosed |
| EP-2496549-A2 | NOVEL NON-CRYSTALLIZING METHACRYLATES, PRODUCTION AND USE THEREOF | Bayer MaterialScience AG (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120219885-A1 | NOVEL NON-CRYSTALLIZING METHACRYLATES, PRODUCTION AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2011054818-A2 | NOVEL NON-CRYSTALLIZING METHACRYLATES, PRODUCTION AND USE THEREOF | BAYER MATERIALSCIENCE AG (DE) | 2011-05-12 | — | — | WO | disclosed |
| US-5028629-A | 2-(Substituted)-N-Hydroxy-N-Alkylcinnamamides | ELI LILLY AND COMPANY (US) | 1991-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630518-B2 | Process for preparing 1,2-benzisothiazoline-3-one | CBR1, SULT1A1, ARSA | FOLH1 4596/4885TSHR 1757/4885LIPG 4436/4885 |
| US-20120219885-A1 | NOVEL NON-CRYSTALLIZING METHACRYLATES, PRODUCTION AND USE THEREOF | MEP1A, MMAB, RHOA | FOLH1 3984/4885TSHR 4836/4885LIPG 3398/4885 |
| US-20240076276-A1 | Process for Preparing 1,2-Benzisothiazoline-3-One | ARSA, AOX1, SULT1A1 | FOLH1 3795/4885TSHR 388/4885LIPG 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.